(Reuters)—Regeneron Pharmaceuticals Inc. said on Tuesday it had identified hundreds of antibodies that could treat or prevent the coronavirus (COVID-19) and was preparing to begin clinical trials by early summer, sending the drugmaker’s shares up 12%.
The company will select the top two antibodies to develop a “cocktail” treatment and scale up its manufacturing to be able to produce 200,000 doses per month by the end of summer.
At least a dozen other drugmakers are currently working on vaccines, antivirals and other treatments to help those infected with the fast-spreading virus, with some antivirals already being used in trials.
Regeneron has a far more robust history of drug development for pandemics, says Oppenheimer analyst Hartaj Singh, noting that during the Ebola outbreak, the U.S. drugmaker’s antibody cocktail demonstrated the greatest effect.
“It seems acute treatments will be needed for hundreds of thousands’ of cases, and there could recurring outbreaks in the future … investors are now ascribing greater value to Regeneron stock for this,” he adds.
Pfizer Inc has agreed to co-develop a vaccine with German drugmaker BioNTech SE as well as develop antiviral treatments that could potentially be used with Gilead Sciences Inc’s antiviral called remdesivir against the coronavirus.
Johnson & Johnson and Sanofi have also teamed up with a U.S. government agency to develop virus vaccine candidates.
Drug developer Moderna Inc., which dosed its first patient with its experimental vaccine on Monday, has made the most headway among companies engaged in coronavirus vaccine development efforts.
“Regeneron is arguably the most efficient antibody developer in the biopharma industry and should deserve a higher valuation for its strong innovation capability,” SVB Leerink analyst Geoffrey Porges says.
The company is also considering testing whether its antibody cocktail could be used along with the vaccines in development, spokeswoman Alexandra Bowie tells Reuters.
“There’s a lot of things racing towards the finish line, all at once. It’s yet to be seen what the exact combination would be,” Bowie adds.
The efforts are a part of its partnership with the U.S. Department of Health and Human Services. Regeneron also said it was working with the U.S. Biomedical Advanced Research and Defense Authority to its increase manufacturing capacity.